|
Reformed incentives system promises better patient access in Europe |
Medicines for Europe |
Tue, 06/11/2024 |
Health & Consumers |
|
Ready to drive access to medicines |
Medicines for Europe |
Wed, 07/24/2019 |
Health & Consumers |
|
Reaction to EU Pharmaceutical legislation: Timely and equitable access for patients and security of supply essential for reform |
Medicines for Europe |
Thu, 04/27/2023 |
Health & Consumers |
|
Protecting health: Active generic and biosimilar policies central to EU pharmaceutical strategy |
Medicines for Europe |
Tue, 03/03/2020 |
Health & Consumers |
|
Proposals on wastewater treatment will jeopardise patient access to medicines without helping green transition |
Medicines for Europe |
Thu, 10/27/2022 |
Health & Consumers |
|
Pharmaceutical legislation reforms must support equitable access to medicine in Central and Eastern Europe and security of medicines supplies |
Medicines for Europe |
Thu, 11/17/2022 |
Health & Consumers |
|
Patients should benefit from greater access under new patent package proposals |
Medicines for Europe |
Fri, 04/28/2023 |
Health & Consumers |
|
Parliament’s Trade Committee votes for jobs and access to medicines with a comprehensive SPC Manufacturing Waiver! |
Medicines for Europe |
Tue, 12/04/2018 |
Health & Consumers |
|
Parliament’s Health Committee (ENVI) introduces constructive amendments to SPC Manufacturing waiver vote in its official opinion to the Parliament’s Legal Committee (JURI). |
Medicines for Europe |
Wed, 11/28/2018 |
Health & Consumers |
|
Parliament’s balanced stand on Unitary SPC regulation rewards innovation via an efficient Unitary SPC system that protects against access to medicines delays |
Medicines for Europe |
Wed, 02/28/2024 |
InfoSociety |
|
Parliament compromise on pharmaceutical legislation accelerates much needed reform |
Medicines for Europe |
Tue, 03/19/2024 |
Health & Consumers |
|
Orphan and paediatric reform should strive to improve access to medicine for rare disease patients and children |
Medicines for Europe |
Fri, 07/30/2021 |
Health & Consumers |
|
Open borders that prioritise essential goods key to medicines supply in Europe |
Medicines for Europe |
Wed, 06/02/2021 |
Health & Consumers |
|
Oncology, the new era for biosimilar medicines |
Medicines for Europe |
Fri, 09/08/2017 |
Health & Consumers |
|
Off-patent medicines ready to drive pharma policy reform for equitable access, availability and security of medicines supply |
Medicines for Europe |
Thu, 06/15/2023 |
Health & Consumers |
|
Off-patent medicines industry marks 30 years of delivering public health impact |
Medicines for Europe |
Wed, 06/12/2024 |
Health & Consumers |
|
Off patent medicines essential for a fairer, healthier, and sustainable Europe says President Christoph Stoller |
Medicines for Europe |
Fri, 04/30/2021 |
Health & Consumers |
|
Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing |
Medicines for Europe |
Wed, 10/07/2020 |
Health & Consumers |
|
Now or never: Europe must seize the Pharma Legislation opportunity to ensure patient access to continuous innovation for existing medicines |
Medicines for Europe |
Tue, 11/07/2023 |
Health & Consumers |
|
No further excuse to delay digital regulatory infrastructure for medicines after COVID-19 pandemic |
Medicines for Europe |
Fri, 02/19/2021 |
Health & Consumers |
|
New safeguards for patient safety as Falsified Medicines Directive comes into force |
Medicines for Europe |
Mon, 02/11/2019 |
Health & Consumers |
|
New report reveals need for pricing and reimbursement and procurement reforms to ensure patient access and healthcare sustainability |
Medicines for Europe |
Mon, 03/01/2021 |
Health & Consumers |
|
New report assesses progress on biosimilar medicine policies across Europe |
Medicines for Europe |
Tue, 03/30/2021 |
Health & Consumers |
|
Medicines for Europe, APOGEN and Fresenius Kabi hold Open Industry Day in Portugal |
Medicines for Europe |
Thu, 11/14/2019 |
Health & Consumers |
|
Medicines for Europe welcomes Competitiveness Council discussion to stop delocalisation of medicine manufacturing. It is time to effectively position Europe as a global hub for the production of medicines. |
Medicines for Europe |
Fri, 11/30/2018 |
Health & Consumers |
|
Medicines for Europe warns strongly against energy rationing for medicines production |
Medicines for Europe |
Wed, 07/20/2022 |
Health & Consumers |
|
Medicines for Europe to join the ISPOR Issue Panel on value added medicines |
Medicines for Europe |
Thu, 10/05/2017 |
Health & Consumers |
|
Medicines for Europe statement on COVID-19 (‘coronavirus’) |
Medicines for Europe |
Fri, 03/13/2020 |
Health & Consumers |
|
Medicines for Europe members publish disclosure of Transfers of Value to the healthcare community |
Medicines for Europe |
Fri, 06/22/2018 |
Health & Consumers |
|
Medicines for Europe joins the Antimicrobial (AMR) One Health Network |
Medicines for Europe |
Tue, 05/09/2023 |
Health & Consumers |
